Exact Sciences is a U.S.-based molecular diagnostics company headquartered in Madison, Wisconsin. Founded in 1995, the company specializes in developing non-invasive tests for early cancer detection and personalized treatment guidance. Its flagship product, Cologuard, is the first FDA-approved stool DNA test for colorectal cancer screening, launched in 2014. Since then, Exact Sciences has expanded its portfolio to include tests for breast, liver, and other cancers, including the Oncotype DX® suite for breast cancer recurrence risk assessment.

The company operates globally, with over 6,500 employees and a presence in more than 120 countries. Exact Sciences is committed to innovation, having acquired several companies to enhance its capabilities, including Genomic Health in 2019 and Thrive Earlier Detection in 2020. In 2024, Exact Sciences received FDA approval for Cologuard Plus, an improved version of its colorectal cancer screening test, which offers higher specificity and reduced false positives.